Tackling hyperinflation

Manufacturers often take unjustified price hikes on existing drugs simply by introducing different formulations or dosing recommendations. These are often known as “hyperinflated.” Regardless of what they are called, spending on these drugs means wasted dollars for our clients. 

We proactively manage this for our clients as part of our formulary management process.

Statistics: 72 drugs removed in 2020. $1.2 billion lower client spend compared to 2018.
We continually monitor the pharmaceutical landscape and evolve our formulary strategy to help clients stay ahead of marketplace trends, while offering members access to clinically appropriate, cost-effective medications.

Dislcaimer

*includes hyperinflated and aberrant drugs